DC Chemicals · Product datasheet

KIN1148 — Datasheet

CAT. NO. DC10518

Product page and current package options

ParameterValue
Chemical NameN-(Benzo[1,2-d:3,4-d']bis(thiazole)-2-yl)-2-naphthamide
CAS No.1428729-56-9
SynonymsKIN1148;N-Benzo[1,2-d;N-(benzo[1,2-d:3,4-d']bis(thiazole)-2-yl)-2-naphthamide;N-([1,3]thiazolo[5,4-e][1,3]benzothiazol-2-yl)naphthalene-2-carboxamide;BCP29251;KIN 1148;AK688999
FormulaC19H11N3OS2
M.Wt361.4401
SMILESS1C(N([H])C(C2C([H])=C([H])C3=C([H])C([H])=C([H])C([H])=C3C=2[H])=O)=NC2C([H])=C([H])C3=C(C1=2)N=C([H])S3
Purity>98%
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

KIN1148, a small-molecule IRF3 agonist, is a novel influenza vaccine adjuvant found to enhance flu vaccine efficacy.

In Vitro

KIN1148 induces the dose-dependent nuclear translocation of IRF3 in PH5CH8 cells and specific activation of IRF3- responsive promoters. KIN1148 also elicits greater induction of endogenous IRF3-dependent ISG54 and OASL expression by PH5CH8 cells[1].

In Vivo

Prime-boost immunization of mice with a suboptimal dose of a monovalent pandemic influenza split virus H1N1 A/California/07/2009 vaccine plus KIN1148 protect against a lethal challenge with mouse-adapted influenza virus (A/California/04/2009) and induce an influenza virusspecific IL-10 and Th2 response by T cells derived from lung and lung-draining lymph nodes. Primeboost immunization with vaccine plus KIN1148, but not prime immunization alone, induce antibodies capable of inhibiting influenza virus hemagglutinin and neutralizing viral infectivity. Nevertheless, a single immunization with vaccine plus KIN1148 provide increased protection over vaccine alone and reduce viral load in the lungs after challenge[1].

References & source

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

Cart

Request quotation